Xencor, Inc. (NASDAQ:XNCR) Director Sells $27,595.46 in Stock

Xencor, Inc. (NASDAQ:XNCR - Get Free Report) Director Ellen Feigal sold 2,993 shares of the company's stock in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $9.22, for a total value of $27,595.46. Following the completion of the transaction, the director now directly owns 19,183 shares in the company, valued at $176,867.26. This trade represents a 13.50% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Xencor Stock Performance

NASDAQ XNCR traded up $0.05 during trading hours on Thursday, hitting $8.36. 835,269 shares of the company's stock traded hands, compared to its average volume of 667,672. Xencor, Inc. has a 52 week low of $7.16 and a 52 week high of $27.24. The firm has a market capitalization of $594.98 million, a P/E ratio of -2.73 and a beta of 0.87. The company has a current ratio of 5.89, a quick ratio of 5.89 and a debt-to-equity ratio of 0.16. The business's fifty day moving average price is $9.07 and its two-hundred day moving average price is $14.70.

Xencor (NASDAQ:XNCR - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.66) earnings per share for the quarter, missing the consensus estimate of ($0.60) by ($0.06). Xencor had a negative return on equity of 31.94% and a negative net margin of 181.17%. The business had revenue of $32.73 million for the quarter, compared to analysts' expectations of $23.44 million. During the same quarter in the prior year, the business earned ($1.11) EPS. The company's revenue was up 104.6% compared to the same quarter last year. Equities research analysts predict that Xencor, Inc. will post -3.68 EPS for the current year.

Hedge Funds Weigh In On Xencor

Institutional investors have recently bought and sold shares of the stock. Inspire Investing LLC increased its position in Xencor by 85.3% in the first quarter. Inspire Investing LLC now owns 32,402 shares of the biopharmaceutical company's stock worth $345,000 after buying an additional 14,913 shares in the last quarter. Goldman Sachs Group Inc. lifted its position in shares of Xencor by 89.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 726,734 shares of the biopharmaceutical company's stock valued at $7,732,000 after buying an additional 344,088 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Xencor by 9.1% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 44,047 shares of the biopharmaceutical company's stock valued at $471,000 after acquiring an additional 3,692 shares during the period. Jacobs Levy Equity Management Inc. increased its holdings in Xencor by 73.9% in the 1st quarter. Jacobs Levy Equity Management Inc. now owns 904,485 shares of the biopharmaceutical company's stock worth $9,624,000 after acquiring an additional 384,509 shares in the last quarter. Finally, BVF Inc. IL raised its stake in Xencor by 19.7% during the 1st quarter. BVF Inc. IL now owns 2,740,141 shares of the biopharmaceutical company's stock worth $29,155,000 after acquiring an additional 451,381 shares during the period.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on XNCR shares. Wells Fargo & Company lowered their price target on Xencor from $37.00 to $33.00 and set an "overweight" rating on the stock in a report on Friday, February 28th. Wedbush reissued an "outperform" rating and issued a $31.00 target price on shares of Xencor in a research report on Wednesday, April 30th. William Blair initiated coverage on shares of Xencor in a research note on Monday, April 21st. They set an "outperform" rating on the stock. Wall Street Zen downgraded shares of Xencor from a "hold" rating to a "sell" rating in a report on Friday, March 14th. Finally, Barclays decreased their price objective on shares of Xencor from $22.00 to $6.00 and set an "underweight" rating for the company in a report on Thursday, May 8th. Two analysts have rated the stock with a sell rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $28.00.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.